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Background: The rate of colonisation, types of ﬁlamentous fungi (ff) and the
clinical signiﬁcance in the CF airway has not been established. A. fumigatus is the
most common fungus isolated from CF patients with other fungi rarely reported.
Detection is highly dependent on culture conditions. Prevalence of ff is believed to
increase with age however, very little data has been reported in children.
The aim was to prospectively study the prevalence and type of ﬁlamentous fungi
present in our paediatric CF population.
Method: All children in our tertiary CF centre were eligible, an adult CF group
was included for comparison. Assessments of LFTs, radiology, sputum analysis for
inﬂammation, bacterial and fungal cultures were undertaken.
Mycology: Sputum plugs or BAL samples were inoculated onto two media, PGCF
and Scedosporium selective agar, and incubated at 30ºC and 37ºC for 21 days.
Fungi were identiﬁed microscopically and by DNA sequencing.
Results: 35 samples were obtained (29 children: BAL n= 10; sputum n= 25) were
analysed. 97% of samples contained fungi.
The most frequent isolate was A. fumigatus (69%) followed by Penicil-
lium spp. (26%). 17 different ﬁlamentous fungi were isolated.
The added use of Scedosporium selective agar enabled the detection of fungi which
would have been missed, including Scedosporium, Bjerkandera and Penicillium spp.
Conclusions:
• Contrary to previous reports, ff were present in the sputum of the majority of
children studied.
• Children <10 y had a high rate of Penicillium isolated not previously reported.
• Fungal culture and prevalence varied depending on media and incubation tem-
perature.
• Further work is required to establish the clinical signiﬁcance in the CF airway.
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Objectives: Scedosporium apiospermum is a saprophytic ubiquitous ﬁlamentous
fungus found at comparable frequency in the environment including potted plants,
polluted soil and water. It is the second most frequent ﬁlamentous fungus that can
be found in cystic ﬁbrosis (CF) patients and its prevalence is reported as 0.7−9%.
The aim of our study was to summarize and present all CF patients who were
colonized by S. apiospermum in their respiratory system during their childhood.
Methods: The CF Center in “Aghia Sophia” Children’s Hospital provides care for
more than 400 patients with CF conﬁrmed by sweat testing and genotyping. Their
medical records were reviewed in order to identify those patients who had a history
of positive respiratory cultures for S. apiospermum. A number of parameters such as
demographic factors, pharmacological treatments and characteristics of the airway
microbiota were also collected.
Results: S. apiospermum was isolated in 10 CF patients and their median age
was 15 years. All patients had exocrine pancreatic dysfunction and half of patients
had at least one DF508 mutation. The median BMI was 19.88 kg/m2, while the
median FEV1 %predicted was 78.65%. Regarding the pharmacological treatments,
four children were receiving inhaled corticosteroids for at least three months before
fungus isolation and nine patients were receiving inhaled antibiotics for a long
period. Six patients had a history of A. fumigatus isolation and seven patients were
chronically or intermittent colonized with Ps. aeruginosa.
Conclusion: A. fumigatus and/or Ps. aeruginosa colonization may increase the
likelihood of S. apiospermum colonization in patients with CF.
155 Aspergillus pulmonary infections in children with cystic
ﬁbrosis (CF): prevalences in three Scandinavian CF centres
M. Skov1, A. Hollsing2, A. Lindblad3, Scandinavian Cystic Fibrosis Study
Consortium. 1Rigshospitalet, CF Centre, BBLC, GGK, Copenhagen, Denmark;
2CF Centre, Pediatric, Uppsala, Sweden; 3CF Centre, Pediatric, Go¨teborg, Sweden
Objectives: Reported prevalence of allergic bronchopulmonary aspergillosis
(ABPA) in CF is around 10%, whereas the prevalence of Aspergillus bronchitis
is unknown. The prevalences in 3 pediatric Scandinavian CF Centres are presented.
Methods: Data from CF children (<18 years) was collected (2012) in a Danish
and two Swedish CF Centres including demography, microbiology and Aspergillus-
serology. Criteria for ABPA and Aspergillus bronchitis were according to CFF
Consensus criteria (2003) and Shosevoy (Chest 2006). Aspergillus speciﬁc treatment
included azoles, high dose iv methylprednisolon and omalizumab.
Results: See the table.
CF Center N Gender Age dF508ho ABPA Aspergillus bronchitis
% Age M/F dF508ho % Age M/F dF508ho
Copenhagen 111 56M/55F 11 57% 6% 15 5/2 4 23% 12 12/14 13
Go¨teborg 45 32M/13F 10 51% 7% 15 3/0 1 4% 15 2/0 1
Uppsala 35 18M/17F 10 31% 3% 15 1/0 1 0
Ages are median (yrs). dF508ho, delF508 homozygous.
Conclusion: The ABPA prevalence (3−7%) was within the previously reported
range. Aspergillus bronchitis (0−23%) had a greatly varied prevalence, and needs
further investigation. ABPA occurs primarily in teens, whereas median age for
Aspergillus bronchitis is lower. In these preliminary data ABPA was more prevalent
in males, whereas no gender difference was found for Aspergillus bronchitis. No
difference in delF508 homozygoty ratio was found. The study is ongoing including
all eight Scandinavian CF Centers.
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Objectives: ABPAs is a complication occurring in 10 to 15% of the CF patients.
In case of late diagnosis bronchial damage can be considerably. A high degree of
suspicion is mandatory and indicators of ABPAs must be followed carefully. We
intend to study facilitators and consequences of ABPAs.
Methods: We performed a case control study relying on data from the Belgian CF
register. One hundred and ﬁfty-ﬁve ABPAs patients matched for age, gender and
P. aeruginosa colonisation were compared to 356 controls. FEV1 decline, infectious
exacerbations and BMI were studied over a period of 10 years before and 10 years
after the index year.
Results: Before the index year mean cumulative FEV1 values are signiﬁcantly lower
in the ABPAs group (p< 0.002), although the decline over the years is comparable.
After the index year mean cumulative FEV1 values remain signiﬁcantly different
between both groups (p< 0.0001) but there is a signiﬁcantly steeper decline in
FEV1 over the 10 years period in the ABPAs group.
Before the index year ABPAs patients spent signiﬁcantly more days in hospital
for IV antibiotic treatment (p< 0.001). This difference persists after the index year
(p< 0.0001).
BMI is signiﬁcantly lower in the ABPAs patient group, both before and after the
index year (p< 0.001).
Conclusion: Lower FEV1, lower BMI and increased need for IV antibiotics seems
to facilitate the development of ABPAs. ABPAs favours accelerated bronchial
damage leading to a further increased need for IV antibiotics and a steeper decline
in FEV1.
